Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib.

The oncologist - 8 Jul 2026

Rahbarlayegh Elnaz, Kesari Santosh

Abstract excerpt

Genetic and molecular alterations in cancer cells can serve as therapeutic targets and enable more precise, individualized treatment strategies. In rare tumors with limited systemic treatment options, molecular profiling may help identify therapeutic opportunities when conventional approaches are exhausted. We report the case of a 72-year-old woman with a long-standing, multiply recurrent clival chordoma and no...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to IDH1 gene
Share to Glycine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 42348221
DOI: 10.1093/oncolo/oyag240
PMCID: PMC13372670

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib.PMID 42348221Read ↗

Clinical development of IDH1 inhibitors for cancer therapy.Semantic proximity Read ↗

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study.Semantic proximity Read ↗

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.Semantic proximity Read ↗

Clinical and radiological response of Maffucci related enchondromas to mutant IDH1 inhibitor Ivosidenib.Semantic proximity Read ↗

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsSemantic proximity Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle PathwaySemantic proximity Read ↗

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.Semantic proximity Read ↗

Genomic profiles and clinical presentation of chordoma.Semantic proximity Read ↗

Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.Semantic proximity Read ↗

From Histology to Multi-Omics: Review of Chordoma Classification and Its Clinical ImplicationsSemantic proximity Read ↗

Mutational analysis of primary and advanced chordoma tissue using next‐generation sequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.